SLAMF7 Overview
Molecule Name
SLAM family member 7
Synonyms
SLAMF7,CD319,CS1,CRACC,19A,FOAP-12
Drug Development Progress
Drugs in Clinical Trials8
Approved Drugs1
Highest Development StageApproved
Target Synonym
CS1，UNQ576/PRO1138，SLAMF7，Novel Ly9，SLAM Family Member 7，Membrane Protein FOAP-12，CD2 Subset 1，Protein 19A，CRACC，CD2-Like Receptor Activating Cytotoxic Cells，CD2-Like Receptor-Activating Cytotoxic Cells，19A24 Protein，CD319，19A，CD319 Antigen，Novel LY9 (Lymphocyte Antigen 9) Like Protein
Background
SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.
SLAMF7 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) | Phase 2 Clinical | University Hospital Würzburg | Multiple Myeloma | Details | |
| dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology) | Phase 1 Clinical | Wuhan Sian Biotechnology Co Ltd | Multiple Myeloma | Details | |
| BCMA-CS1 cCAR T-cell therapy | Phase 1 Clinical | iCell Gene Therapeutics LLC | Multiple Myeloma | Details | |
| SA102-CAR-T | SA-102; SA102 | Phase 1 Clinical | Wuhan Sian Biotechnology Co Ltd | Multiple Myeloma | Details |
| WS-CART-CS1 | WS-CART-CS1 | Phase 1 Clinical | Paula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of Medicine | Multiple Myeloma | Details |
| MB-104 | MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR | Phase 1 Clinical | City Of Hope National Medical Center | Glioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| CS1 Targeted CAR T-cells (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Elotuzumab | PDL-063; HuLuc-63; BMS-901608 | Approved | Abbvie Inc, Bristol-Myers Squibb Company | Empliciti | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2015-11-30 | Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential | Details |